Claudin 4 is differentially expressed between ovarian cancer subtypes and plays a role in spheroid formation

International Journal of Molecular Sciences

Volumn 12, Issue 2, 2011, Pages 1334-1358

  Boylan, Kristin L M ^a   Misemer, Benjamin ^a   DeRycke, Melissa S ^a   Andersen, John D ^a   Harrington, Katherine M ^a   Kalloger, Steve E ^b   Gilks, C Blake ^b   Pambuccian, Stefan E ^a   Skubitz, Amy P N ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Ascites; Biomarker; Claudin 4; Ovarian cancer; Spheroid

Indexed keywords

BETA1 INTEGRIN; CADHERIN; CLAUDIN 4; TUMOR MARKER;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CANCER; OVERALL SURVIVAL; PROTEIN DENATURATION; PROTEIN LOCALIZATION; PROTEOMICS; SPHEROID CELL; TISSUE MICROARRAY; TUMOR GROWTH; ASCITES; CARCINOMA; DIFFERENTIAL DIAGNOSIS; FEMALE; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ASCITES; CARCINOMA; CELL LINE, TUMOR; CLAUDIN-4; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; OVARIAN NEOPLASMS; SPHEROIDS, CELLULAR; TUMOR MARKERS, BIOLOGICAL;

EID: 79952259789     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms12021334     Document Type: Article

References (72)

1. Boyle, P.; Levin, B. World Cancer Report 2008; International Agency for Research on Cancer: Lyon, France, 2008.
2. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59, 225-249.
3. Shield, K.; Ackland, M.L.; Ahmed, N.; Rice, G.E. Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecol. Oncol. 2009, 113, 143-148.
4. Burleson, K.M.; Boente, M.P.; Pambuccian, S.E.; Skubitz, A.P. Disaggregation and invasion of ovarian carcinoma ascites spheroids. J. Transl. Med. 2006, 4, 6.
5. Burleson, K.M.; Casey, R.C.; Skubitz, K.M.; Pambuccian, S.E.; Oegema, T.R., Jr.; Skubitz, A.P. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol. Oncol. 2004, 93, 170-181.
6. Burleson, K.M.; Hansen, L.K.; Skubitz, A.P. Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clin. Exp. Metastasis 2004, 21, 685-697.
7. Shield, K.; Riley, C.; Quinn, M.A.; Rice, G.E.; Ackland, M.L.; Ahmed, N. Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J. Carcinog. 2007, 6, 11.
8. Sodek, K.L.; Ringuette, M.J.; Brown, T.J. Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int. J. Cancer 2009, 124, 2060-2070.
9. Desoize, B.; Jardillier, J. Multicellular resistance: a paradigm for clinical resistance? Crit. Rev. Oncol. Hematol. 2000, 36, 193-207.
10. Yoshida, Y.; Kurokawa, T.; Nishikawa, Y.; Orisa, M.; Kleinman, H.K.; Kotsuji, F. Laminin-1-derived scrambled peptide AG73T disaggregates laminin-1-induced ovarian cancer cell spheroids and improves the efficacy of cisplatin. Int. J. Oncol. 2008, 32, 673-681.
11. Bignotti, E.; Tassi, R.A.; Calza, S.; Ravaggi, A.; Romani, C.; Rossi, E.; Falchetti, M.; Odicino, F.E.; Pecorelli, S.; Santin, A.D. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol. Oncol. 2006, 103, 405-416.
12. Hibbs, K.; Skubitz, K.M.; Pambuccian, S.E.; Casey, R.C.; Burleson, K.M.; Oegema, T.R., Jr.; Thiele, J.J.; Grindle, S.M.; Bliss, R.L.; Skubitz, A.P. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am. J. Pathol. 2004, 165, 397-414.
13. Hough, C.D.; Sherman-Baust, C.A.; Pizer, E.S.; Montz, F.J.; Im, D.D.; Rosenshein, N.B.; Cho, K.R.; Riggins, G.J.; Morin, P.J. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 2000, 60, 6281-6287.
14. Lu, K.H.; Patterson, A.P.; Wang, L.; Marquez, R.T.; Atkinson, E.N.; Baggerly, K.A.; Ramoth, L.R.; Rosen, D.G.; Liu, J.; Hellstrom, I.; Smith, D.; Hartmann, L.; Fishman, D.; Berchuck, A.; Schmandt, R.; Whitaker, R.; Gershenson, D.M.; Mills, G.B.; Bast, R.C., Jr. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 2004, 10, 3291-3300.
15. Santin, A.D.; Zhan, F.; Bellone, S.; Palmieri, M.; Cane, S.; Bignotti, E.; Anfossi, S.; Gokden, M.; Dunn, D.; Roman, J.J.; O'Brien, T.J.; Tian, E.; Cannon, M.J.; Shaughnessy, J., Jr.; Pecorelli, S. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int. J. Cancer 2004, 112, 14-25.
16. Morin, P.J. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res. 2005, 65, 9603-9606.
17. Singh, A.B.; Sharma, A.; Dhawan, P. Claudin family of proteins and cancer: an overview. J. Oncol. 2010, 2010, 541957.
18. Cohn, M.L.; Goncharuk, V.N.; Diwan, A.H.; Zhang, P.S.; Shen, S.S.; Prieto, V.G. Loss of claudin-1 expression in tumor-associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms. J. Cutan. Pathol. 2005, 32, 533-536.
19. Kim, T.H.; Huh, J.H.; Lee, S.; Kang, H.; Kim, G.I.; An, H.J. Down-regulation of claudin-2 in breast carcinomas is associated with advanced disease. Histopathology 2008, 53, 48-55.
20. Miyamoto, K.; Kusumi, T.; Sato, F.; Kawasaki, H.; Shibata, S.; Ohashi, M.; Hakamada, K.; Sasaki, M.; Kijima, H. Decreased expression of claudin-1 is correlated with recurrence status in esophageal squamous cell carcinoma. Biomed. Res. 2008, 29, 71-76.
21. Morohashi, S.; Kusumi, T.; Sato, F.; Odagiri, H.; Chiba, H.; Yoshihara, S.; Hakamada, K.; Sasaki, M.; Kijima, H. Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int. J. Mol. Med. 2007, 20, 139-143.
22. Ohtani, S.; Terashima, M.; Satoh, J.; Soeta, N.; Saze, Z.; Kashimura, S.; Ohsuka, F.; Hoshino, Y.; Kogure, M.; Gotoh, M. Expression of tight-junction-associated proteins in human gastric cancer: downregulation of claudin-4 correlates with tumor aggressiveness and survival. Gastric. Cancer 2009, 12, 43-51.
23. Oshima, T.; Kunisaki, C.; Yoshihara, K.; Yamada, R.; Yamamoto, N.; Sato, T.; Makino, H.; Yamagishi, S.; Nagano, Y.; Fujii, S.; Shiozawa, M.; Akaike, M.; Wada, N.; Rino, Y.; Masuda, M.; Tanaka, K.; Imada, T. Reduced expression of the claudin-7 gene correlates with venous invasion and liver metastasis in colorectal cancer. Oncol. Rep. 2008, 19, 953-959.
24. Sauer, T.; Pedersen, M.K.; Ebeltoft, K.; Naess, O. Reduced expression of Claudin-7 in fine needle aspirates from breast carcinomas correlate with grading and metastatic disease. Cytopathology 2005, 16, 193-198.
25. Sung, C.O.; Han, S.Y.; Kim, S.H. Low Expression of Claudin-4 is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma. Ann. Surg. Oncol. 2011, 18, 273-281.
26. Ueda, J.; Semba, S.; Chiba, H.; Sawada, N.; Seo, Y.; Kasuga, M.; Yokozaki, H. Heterogeneous expression of claudin-4 in human colorectal cancer: decreased claudin-4 expression at the invasive front correlates cancer invasion and metastasis. Pathobiology 2007, 74, 32-41.
27. Usami, Y.; Chiba, H.; Nakayama, F.; Ueda, J.; Matsuda, Y.; Sawada, N.; Komori, T.; Ito, A.; Yokozaki, H. Reduced expression of claudin-7 correlates with invasion and metastasis in squamous cell carcinoma of the esophagus. Hum. Pathol. 2006, 37, 569-577.
28. Agarwal, R.; D'Souza, T.; Morin, P.J. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res. 2005, 65, 7378-7385.
29. Landers, K.A.; Samaratunga, H.; Teng, L.; Buck, M.; Burger, M.J.; Scells, B.; Lavin, M.F.; Gardiner, R.A. Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer. Br. J. Cancer 2008, 99, 491-501.
30. Lanigan, F.; McKiernan, E.; Brennan, D.J.; Hegarty, S.; Millikan, R.C.; McBryan, J.; Jirstrom, K.; Landberg, G.; Martin, F.; Duffy, M.J.; Gallagher, W.M. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int. J. Cancer 2009, 124, 2088-2097.
31. Long, H.; Crean, C.D.; Lee, W.H.; Cummings, O.W.; Gabig, T.G. Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res. 2001, 61, 7878-7881.
32. Rangel, L.B.; Agarwal, R.; D'Souza, T.; Pizer, E.S.; Alo, P.L.; Lancaster, W.D.; Gregoire, L.; Schwartz, D.R.; Cho, K.R.; Morin, P.J. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin. Cancer Res. 2003, 9, 2567-2575.
33. Takehara, M.; Nishimura, T.; Mima, S.; Hoshino, T.; Mizushima, T. Effect of claudin expression on paracellular permeability, migration and invasion of colonic cancer cells. Biol. Pharm. Bull. 2009, 32, 825-831.
34. Morita, K.; Tsukita, S.; Miyachi, Y. Tight junction-associated proteins (occludin, ZO-1, claudin-1, claudin-4) in squamous cell carcinoma and Bowen's disease. Br. J. Dermatol. 2004, 151, 328-334.
35. Sato, N.; Fukushima, N.; Maitra, A.; Iacobuzio-Donahue, C.A.; van Heek, N.T.; Cameron, J.L.; Yeo, C.J.; Hruban, R.H.; Goggins, M. Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am. J. Pathol. 2004, 164, 903-914.
36. Gress, T.M.; Muller-Pillasch, F.; Geng, M.; Zimmerhackl, F.; Zehetner, G.; Friess, H.; Buchler, M.; Adler, G.; Lehrach, H. A pancreatic cancer-specific expression profile. Oncogene 1996, 13, 1819-1830.
37. Litkouhi, B.; Kwong, J.; Lo, C.M.; Smedley, J.G., 3rd; McClane, B.A.; Aponte, M.; Gao, Z.; Sarno, J.L.; Hinners, J.; Welch, W.R.; Berkowitz, R.S.; Mok, S.C.; Garner, E.I. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia 2007, 9, 304-314.
38. Zhu, Y.; Brannstrom, M.; Janson, P.O.; Sundfeldt, K. Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. Int. J. Cancer 2006, 118, 1884-1891.
39. Crum, C.P.; Drapkin, R.; Miron, A.; Ince, T.A.; Muto, M.; Kindelberger, D.W.; Lee, Y. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr. Opin. Obstet. Gynecol. 2007, 19, 3-9.
40. Gilks, C.B.; Ionescu, D.N.; Kalloger, S.E.; Kobel, M.; Irving, J.; Clarke, B.; Santos, J.; Le, N.; Moravan, V.; Swenerton, K. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum. Pathol. 2008, 39, 1239-1251.
41. Soini, Y.; Talvensaari-Mattila, A. Expression of claudins 1, 4, 5, and 7 in ovarian tumors of diverse types. Int. J. Gynecol. Pathol. 2006, 25, 330-335.
42. Lechpammer, M.; Resnick, M.B.; Sabo, E.; Yakirevich, E.; Greaves, W.O.; Sciandra, K.T.; Tavares, R.; Noble, L.C.; DeLellis, R.A.; Wang, L.J. The diagnostic and prognostic utility of claudin expression in renal cell neoplasms. Mod. Pathol. 2008, 21, 1320-1329.
43. Kleinberg, L.; Holth, A.; Trope, C.G.; Reich, R.; Davidson, B. Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Hum. Pathol. 2008, 39, 747-757.
44. Ivascu, A.; Kubbies, M. Diversity of cell-mediated adhesions in breast cancer spheroids. Int. J. Oncol. 2007, 31, 1403-1413.
45. Bates, R.C.; Edwards, N.S.; Yates, J.D. Spheroids and cell survival. Crit. Rev. Oncol. Hematol. 2000, 36, 61-74.
46. Frankel, A.; Rosen, K.; Filmus, J.; Kerbel, R.S. Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl-X(L). Cancer Res. 2001, 61, 4837-4841.
47. Makhija, S.; Taylor, D.D.; Gibb, R.K.; Gercel-Taylor, C. Taxol-induced bcl-2 phosphorylation in ovarian cancer cell monolayer and spheroids. Int. J. Oncol. 1999, 14, 515-521.
48. Stewart, J.J.; White, J.T.; Yan, X.; Collins, S.; Drescher, C.W.; Urban, N.D.; Hood, L.; Lin, B. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol. Cell. Proteomics 2006, 5, 433-443.
49. Heinzelmann-Schwarz, V.A.; Gardiner-Garden, M.; Henshall, S.M.; Scurry, J.; Scolyer, R.A.; Davies, M.J.; Heinzelmann, M.; Kalish, L.H.; Bali, A.; Kench, J.G.; Edwards, L.S.; Vanden Bergh, P.M.; Hacker, N.F.; Sutherland, R.L.; O'Brien, P.M. Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin. Cancer Res. 2004, 10, 4427-4436.
50. D'Souza, T.; Indig, F.E.; Morin, P.J. Phosphorylation of claudin-4 by PKCepsilon regulates tight junction barrier function in ovarian cancer cells. Exp. Cell Res. 2007, 313, 3364-3375.
51. Tanaka, M.; Kamata, R.; Sakai, R. EphA2 phosphorylates the cytoplasmic tail of Claudin-4 and mediates paracellular permeability. J. Biol. Chem. 2005, 280, 42375-42382.
52. Casey, R.C.; Burleson, K.M.; Skubitz, K.M.; Pambuccian, S.E.; Oegema, T.R., Jr.; Ruff, L.E.; Skubitz, A.P. Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am. J. Pathol. 2001, 159, 2071-2080.
53. Casey, R.C.; Koch, K.A.; Oegema, T.R., Jr.; Skubitz, K.M.; Pambuccian, S.E.; Grindle, S.M.; Skubitz, A.P. Establishment of an in vitro assay to measure the invasion of ovarian carcinoma cells through mesothelial cell monolayers. Clin. Exp. Metastasis 2003, 20, 343-356.
54. L'Esperance, S.; Bachvarova, M.; Tetu, B.; Mes-Masson, A.M.; Bachvarov, D. Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids. BMC Genomics 2008, 9, 99.
55. Katahira, J.; Inoue, N.; Horiguchi, Y.; Matsuda, M.; Sugimoto, N. Molecular cloning and functional characterization of the receptor for Clostridium perfringens enterotoxin. J. Cell. Biol. 1997, 136, 1239-1247.
56. McClane, B.A. Clostridium perfringens enterotoxin acts by producing small molecule permeability alterations in plasma membranes. Toxicology 1994, 87, 43-67.
57. Moriwaki, K.; Tsukita, S.; Furuse, M. Tight junctions containing claudin 4 and 6 are essential for blastocyst formation in preimplantation mouse embryos. Dev. Biol. 2007, 312, 509-522.
58. Kondoh, M.; Masuyama, A.; Takahashi, A.; Asano, N.; Mizuguchi, H.; Koizumi, N.; Fujii, M.; Hayakawa, T.; Horiguchi, Y.; Watanbe, Y. A novel strategy for the enhancement of drug absorption using a claudin modulator. Mol. Pharmacol. 2005, 67, 749-756.
59. Shaw, T.J.; Senterman, M.K.; Dawson, K.; Crane, C.A.; Vanderhyden, B.C. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol. Ther. 2004, 10, 1032-1042.
60. Subramanian, I.V.; Bui Nguyen, T.M.; Truskinovsky, A.M.; Tolar, J.; Blazar, B.R.; Ramakrishnan, S. Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival. Cancer Res. 2006, 66, 4319-4328.
61. Skubitz, A.P.; Campbell, K.D.; Goueli, S.; Skubitz, K.M. Association of beta 1 integrin with protein kinase activity in large detergent resistant complexes. FEBS Lett. 1998, 426, 386-391.
62. Kruk, P.A.; Maines-Bandiera, S.L.; Auersperg, N. A simplified method to culture human ovarian surface epithelium. Lab. Invest. 1990, 63, 132-136.
63. Nicosia, S.V.; Wilbanks, G.D.; Saunders, B.; Mayer, J.; Cardosi, R.J.; Kruk, P.A.; Cheng, J.; Bai, W.; Coppola, D.; Fiorica, J. Cytology of human ovarian surface epithelial brushings. Cancer 2004, 102, 1-10.
64. Fronhoffs, S.; Totzke, G.; Stier, S.; Wernert, N.; Rothe, M.; Bruning, T.; Koch, B.; Sachinidis, A.; Vetter, H.; Ko, Y. A method for the rapid construction of cRNA standard curves in quantitative real-time reverse transcription polymerase chain reaction. Mol. Cell. Probes 2002, 16, 99-110.
65. Andersen, J.D.; Boylan, K.L.; Xue, F.S.; Anderson, L.B.; Witthuhn, B.A.; Markowski, T.W.; Higgins, L.; Skubitz, A.P. Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis. Electrophoresis 2010, 31, 599-610.
66. DeRycke, M.S.; Andersen, J.D.; Harrington, K.M.; Pambuccian, S.E.; Kalloger, S.E.; Boylan, K.L.; Argenta, P.A.; Skubitz, A.P. S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival. Am. J. Clin. Pathol. 2009, 132, 846-856.
67. McCluggage, W.G. My approach to and thoughts on the typing of ovarian carcinomas. J. Clin. Pathol. 2008, 61, 152-163.
68. Soslow, R.A. Histologic subtypes of ovarian carcinoma: an overview. Int. J. Gynecol. Pathol. 2008, 27, 161-174.
69. Silverberg, S.G. Histopathologic grading of ovarian carcinoma: a review and proposal. Int. J. Gynecol. Pathol. 2000, 19, 7-15.
70. Cocco, E.; Casagrande, F.; Bellone, S.; Richter, C.E.; Bellone, M.; Todeschini, P.; Holmberg, J.C.; Fu, H.H.; Montagna, M.K.; Mor, G.; Schwartz, P.E.; Arin-Silasi, D.; Azoudi, M.; Rutherford, T.J.; Abu-Khalaf, M.; Pecorelli, S.; Santin, A.D. Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer. BMC Cancer 2010, 10, 349.
71. Kakutani, H.; Kondoh, M.; Saeki, R.; Fujii, M.; Watanabe, Y.; Mizuguchi, H.; Yagi, K. Claudin-4-targeting of diphtheria toxin fragment A using a C-terminal fragment of Clostridium perfringens enterotoxin. Eur. J. Pharm. Biopharm. 2010, 75, 213-217.
72. Ebihara, C.; Kondoh, M.; Hasuike, N.; Harada, M.; Mizuguchi, H.; Horiguchi, Y.; Fujii, M.; Watanabe, Y. Preparation of a claudin-targeting molecule using a C-terminal fragment of Clostridium perfringens enterotoxin. J. Pharmacol. Exp. Ther. 2006, 316, 255-260.